Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IMC-C103C |
Synonyms | |
Therapy Description |
IMC-C103C is a T-cell receptor (TCR) that targets MAGEA4 and is fused with an anti-CD3 single-chain variable fragment (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IMC-C103C | IMC C103C|IMC C103C | IMC-C103C is a T-cell receptor (TCR) that targets MAGEA4 and is fused with an anti-CD3 single-chain variable fragment (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03973333 | Phase Ib/II | Atezolizumab + IMC-C103C IMC-C103C | Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab | Withdrawn | USA | GBR | ESP | 0 |